Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00225550 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
A Phase 1 study, sponsored by Adherex Technologies.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00225550: Clinical Trial Phase 1 study, sponsored by Adherex Technologies.
NCT00225550 is a Phase 1 study that was terminated before completion, run by Adherex Technologies. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00225550, a Phase 1 study, was terminated before completion, sponsored by Adherex Technologies.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin. This study will identify the amount of ADH-1 that subjects can tolerate.
Interventions
- DRUG ADH -1 (Exherin™)
Trial Details
| Field | Value |
|---|---|
| Phase | Phase 1 |
Why NCT00225550 stopped before completion
NCT00225550 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which ADH -1 (Exherin™) is the first listed.
NCT00225550 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00225550 about?
NCT00225550 is a clinical study titled "A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors". N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with incurable, solid tumors with a protein biomarker called N-cadherin...
What is the current status of trial NCT00225550?
This trial is currently terminated. It is a Phase 1 study.
What interventions are being tested in trial NCT00225550?
The interventions under investigation include: ADH -1 (Exherin™) (DRUG).
Who is sponsoring clinical trial NCT00225550?
This trial is sponsored by Adherex Technologies, which has 6 total clinical trials registered on ClinicalTrials.gov.